Polatuzumab vedotin, an antibody–drug conjugate targeting CD79b, has shown efficacy in relapsed/refractory DLBCL, offering a therapeutic option for patients who have failed prior treatments [20,21]. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.